Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Selumetinib · Koselugo, ARRY-886

Small molecule · Inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1) and mitogen-activated protein kinase kinase 2 (MAP2K2) · developed by Astrazeneca

Approved FDA, Apr 2020
AZN Developer
1 Registered trials

What is Selumetinib?

Selumetinib is a small-molecule kinase inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway in the RAS-RAF-MEK-ERK cascade. It is studied in non-small cell lung cancer, and it is used in neurofibromatosis type 1 with plexiform neurofibromas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Koselugo, ARRY-886, AZD-6244, AZD6244; ARRY-142886
Drug type
Small molecule
Targets
mitogen-activated protein kinase kinase 1 (MAP2K1), mitogen-activated protein kinase kinase 2 (MAP2K2)
Mechanism
Inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1) and mitogen-activated protein kinase kinase 2 (MAP2K2)
Pathways
RAF-MEK-ERK pathway, ERK phosphorylation
Therapy area
Oncology
Developer
Astrazeneca (AZN)
FDA status
Approved as Koselugo (April 10, 2020), NDA213756 · FDA label
UNII
6UH91I579U

✅ FDA-approved uses

From the indications section of the FDA label (version of May 26, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04924608 Phase 3 Neurofibromatosis 1 Active not recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on MAP2K1 / MAP2K2

More from Astrazeneca

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Selumetinib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.